The poster presentations will include preclinical characterization data for a highly potent inhibitor of KRAS G12D that is selective against wild-type KRAS, a highly potent and isoform-selective pan-KRAS inhibitor with activity against a broad spectrum of the most common activating KRAS mutations and high selectivity over wild-type HRAS and NRAS, and a fully human monoclonal anti-Nectin-4 antibody conjugated to a topoisomerase I (TOPO 1) inhibitor.

Presentation Title: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

Abstract Number: B115

Presentation Date & Time: Friday October 13, 12:30pm – 4:00pm ET

Session: Poster Session B

Presenter: Chandrasekar Iyer

Presentation Title: Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS

Abstract Number: B116

Presentation Date & Time: Friday October 13, 12:30pm – 4:00pm ET

Session: Poster Session B

Presenter: Lourdes Prieto Vallejo

Presentation Title: Preclinical characterization of ETx-22, a next-generation antibody drug conjugate (ADC) targeting Nectin-4

Abstract Number: B128

Presentation Date & Time: Friday October 13, 12:30pm – 4:00pm ET

Session: Poster Session B

Presenter: Joanna Fares